Efficacy and safety of ciclesonide in the treatment of 24,037 asthmatic patients in routine medical care

Respiratory Medicine

Volumn 105, Issue 2, 2011, Pages 186-194

  Vogelmeier, Claus F ^a   Hering, Thomas ^b   Lewin, Thomas ^c   Sander, Peter ^c   Bethke, Thomas D ^c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Pneumology Practice ^*  (Germany)

^c Nycomed GmbH   (Germany)

Author keywords

Asthma; Ciclesonide; Efficacy; Inhaled corticosteroid; Real life study; Safety

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CICLESONIDE; NITRIC OXIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CHILD; COUGHING; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GERMANY; HEART FAILURE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SLEEP; THROAT IRRITATION; THRUSH;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ALLERGIC AGENTS; ASTHMA; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FORCED EXPIRATORY VOLUME; GERMANY; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PREGNENEDIONES; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 78651403394     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.09.016     Document Type: Article

References (44)

1. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) Available from: www.ginasthma.org 2008 [Date last updated, 2008]
2. J.D. Skoner, T.J. Schaffner, C.A. Schad, A.Y. Kwon, and D.P. Skoner Addressing steroid phobia: improving the risk-benefit ratio with new agents Allergy Asthma Proc 29 4 2008 358 364
3. F. Cerasoli Developing the ideal inhaled corticosteroid Chest 130 2006 5S 64S
4. R. Nave Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide Clin Pharmacokinet 48 2009 243 252
5. H. Derendorf Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide J Clin Pharmacol 47 2007 782 789
6. H. Derendorf Relevant pharmacokinetic parameters for determining efficacy and safety in inhaled corticosteroids Eur Respir Rev 13 90 2004 62 65
7. C.L. Leach, T.D. Bethke, R.J. Boudreau, B.E. Hasselquist, A. Drollmann, P. Davidson, and W. Wurst Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers J Aerosol Med 19 2006 117 126
8. N.E. Mealy Ciclesonide Drugs Future 26 11 2001 1033 1091
9. M.G. Belvisi Preclinical pharmacology of ciclesonide Eur Respir Rev 13 90 2004 60 68
10. K.R. Chapman, P. Patel, A.D. D'Urzo, M. Alexander, S. Mehra, C. Oedekoven, R. Engelstätter, and L.P. Boulet Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma Allergy 60 2005 330 337
11. D.S. Postma, C. Sevette, Y. Martinat, N. Schlösser, J. Aumann, and H. Kafé Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening Eur Respir J 17 2001 1083 1088
12. C.G. Langdon, M. Adler, S. Mehra, M. Alexander, and A. Drollmann Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma Respir Med 99 2005 1275 1285
13. B.J. O'Connor, S. Kilfeather, and D. Cheung Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks Eur Respir J 20 Suppl. 38 2002 Abstract 2579
14. D.S. Pearlman, W.E. Berger, E. Kerwin, C. Laforce, S. Kundu, and D. Banerji Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma J Allergy Clin Immunol 116 6 2005 1206 1212
15. J.C. Dubus, C. Marguet, A. Deschildre, L. Mely, P. Le Roux, J. Brouard, and L. Huiart Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device Allergy 56 2001 944 948
16. J. Bousquet Safety and efficacy of inhaled corticosteroids Eur Respir Rev 13 90 2004 69 72
17. E. Derom, V. Van De Velde, S. Marissens, R. Engelstätter, W. Vincken, and R. Pauwels Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway-responsiveness to adenosine 5'monophosphate in asthmatic patients Pulm Pharmacol Ther 18 2005 328 336
18. D.P. Skoner, J. Maspero, and D. Banerji Ciclesonide Pediatric Growth Study Group. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma Pediatrics 121 2008 e1 e14
19. US Department of Health and Human Services, Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER) Guidance for Industry - Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment Available from: March 2005
20. International Society for PharmacoEpidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practice (GPP) Available from: 2009 ISPE Bethesda [issued 1996, revised August 2004 & April 2007]
21. International Epidemiological Association (IEA) European Federation Good Epidemiological Practice (GEP) - IEA Guidelines for proper conduct of epidemiological research November 2007
22. Verband Forschender Arzneimittelhersteller e.V VFAEmpfehlungen zur Verbesserung der Qualität und Transparenz von nicht-interventionellen Studien. 31.01. 2007 2007 VFA Berlin Available from:
23. S. Holgate, H. Bisgaard, L. Bjermer, T. Haahtela, J. Haughney, R. Horne, A. McIvor, S. Palkonen, D.B. Price, M. Thomas, E. Valovirta, and U. Wahn The Brussels Declaration: the need for change in asthma management Eur Respir J 32 6 2008 1433 1442
24. D. Price, D. Ryan, L. Pearce, and F. Bride The AIR study: asthma in real life Asthma J 4 1999 74 77
25. L. Borderias, G. Mincewicz, P.L. Paggiaro, M. Guilera, V. Sazonov Kocevar, S.D. Taylor, and X. Badia Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study Curr Med Res Opin 23 2007 721 730
26. R.H. Stanford, A. Fuhlbrigge, A. Riedel, G.G. Rey, and D.A. Stempel An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes Curr Med Res Opin 24 2008 3141 3148
27. N. Barnes, M. Thomas, D. Price, and H. Tate The national montelukast survey J Allergy Clin Immunol 115 2005 47 54
28. J.C. Virchow, A. Mehta, L. Ljungblad, H. Mitfessel the MONICA study group Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic Asthma (MONICA) study Respir Med 104 5 2010 644 651
29. P.K. Keith, C. Koch, M. Djandji, J. Bouchard, E. Psaradellis, J.S. Sampalis, R.R. Schellenberg, and R.A. McIvor Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial) Can Respir J 16 Suppl. A 2009 17A 31A
30. J.M. FitzGerald, S. Foucart, S. Coyle, J. Sampalis, D. Haine, E. Psaradellis, and R.A. McIvor Montelukast as add-on therapy to inhaled corticosteroids in the management of asthma (the SAS trial) Can Respir J 16 Suppl. A 2009 5A 14A
31. M. Thomas, J. von Ziegenweidt, A.J. Lee, and D. Price High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: an observational study J Allergy Clin Immunol 123 2009 116 121.e10
32. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG) Arzneimittelgesetz in der Fassung der Bekanntmachung vom 12. Dezember 2005 (BGBl. I S. 3394), das durch Artikel 1 der Verordnung vom 28. September 2009 (BGBl. I S. 3172) geändert worden ist Available from: 2009 Bundesministerium der Justiz Berlin
33. D.G. Altman, K.F. Schulz, D. Moher, M. Egger, F. Davidoff, D. Elbourne, P.C. Gøtzsche, T. Lang Consort Group (Consolidated Standards of Reporting Trials) The revised CONSORT statement for reporting randomized trials: explanation and elaboration Ann Intern Med 134 8 2001 663 694
34. Summary of Product Characteristics. Alvesco® 80 μg and 160 μg; September 2009.
35. Guideline on the use of statistical signal detection methods in the eudravigilance data analysis system vol. 16 November 2006 EMEA London Doc. Ref. EMEA/106464/2006
36. T.T. Hansel, O. Benezet, H. Kafé, H.H. Ponitz, D. Cheung, R. Engelstätter, and P.J. Barnes A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma Clin Ther 28 2006 906 920
37. P. Niphadkar, K. Jagannath, J.M. Joshi, N. Awad, H. Boss, S. Hellbardt, and D.A. Gadgil Comparison of the efficacy of ciclesonide 160 μg QD and budesonide 200 μg BID in adults with persistent asthma: a phase III, randomized, doubly-dummy, open-label study Clin Ther 27 2005 1752 1763
38. A. von Berg, R. Engelstätter, P. Minic, M. Sréckovic, M.L.G. Garcia, T. Latos, J.H. Vermeulen, S. Leichtl, S. Hellbardt, and T.D. Brthke Comparison of the efficacy and safety of ciclesonide 160 μg once daily vs. budesonide 400 μg once daily in children with asthma Pediatr Allergy Immunol 18 2007 391 400
39. S. Pedersen, R. Engelstätter, H.J. Weber, S. Hirsch, L. Barkai, A. Emeryk, H. Weber, and J. Vermeulen Efficacy and safety of ciclesonode once daily and fluticasone propionate twice daily in children with asthma Pulm Pharmacol Ther 22 2009 214 220
40. W.E. Berger, E. Kerwin, D.I. Bernstein, A. Pedinoff, G. Bensch, and J. Karafilidis Efficacy and safety evaluation of ciclesonide in subjects with mild-to-moderate asthma not currently using inhaled corticosteroids Allergy Asthma Proc 30 2009 304 314
41. R.A. Nathan, L. Kanter, and N.K. Ostrom Ciclesonide improves health-related quality of life in adults and adolescents with mild-to-moderate persistent asthma Allergy Asthma Proc 29 2008 521 527
42. H. Magnussen, J. Hofman, P. Staneta, J.P. Lawo, M. Hellwig, and R. Engelstätter Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma J Asthma 44 2007 555 563
43. E. Lopez-Gonzalez, M.T. Herdeiro, and A. Figueiras Determinants of under-reporting of adverse drug reactions: a systematic review Drug Saf 32 1 2009 19 31
44. L. Hazell, and S.A. Shakir Under-reporting of adverse drug reactions: a systematic review Drug Saf 29 5 2006 385 396